期刊文献+

表皮生长因子受体、p53、Ki-67在三阴性乳腺癌中的表达及其意义 被引量:8

Expression of endothelial growth factor receptor, p53, Ki-67 in human triple negative breast carcinoma and their significances
原文传递
导出
摘要 目的 探讨表皮生长因子受体(EGFR)、p53、Ki-67在三阴性乳腺癌(TNBC)中的表达及其意义.方法 回顾性分析53例TNBC和128例非三阴性乳腺癌(NTNBC)临床病理特征,并应用免疫组织化学方法检测EGFR、p53、Ki-67在两者之间的表达差异.结果 TNBC与NTNBC淋巴结转移发生率差异无统计学意义[56.6%(30/53)比43.0%(55/128),P>0.05],组织学Ⅰ级[9.4%(5/53)与32.8%(42/128)]、Ⅲ级[50.9%(27/53)与22.7%(29/128)]所占比例差异有统计学意义(P<0.05);TNBC中浸润性小叶癌较少[5.7%(3/53)],髓样癌较多[15.1%(8/53)],与NTNBC [19.5%(25/128)、3.1%(4/128)]相比差异有统计学意义(P<0.05);EGFR、p53、Ki-67在TNBC与NTNBC中的表达率分别为62.3%(33/53)与25.0%(32/128)、71.7%(38/53)与47.7%(61/128)、84.9%(45/53)与70.3%(90/128),差异均有统计学意义(均P< 0.05).结论 TNBC有其独特的临床病理特征,EGFR、p53、Ki-67在TNBC中高表达,提示其恶性程度高,侵袭性强,预后差,EGFR、p53、Ki-67表达可以作为评估TNBC预后的重要参考因素. Objective To investigate the expression and significance of endothelial growth factor receptor (EGFR),p53,Ki-67 in human triple negative breast carcinoma (TNBC).Methods The clinicopathologic features of 53 cases of human TNBC and 128 cases of non TNBC (NTNBC) were analysed comparatively,and the expression of EGFR,p53,Ki-67 in the two groups were examined using immunohistochemical method.Results There was no significant difference of lymph node metastasis between TNBC and NTNBC in [56.6 % (30/53) vs 43.0 % (55/128),P 〉 0.05],but their was the significant difference in histological grade Ⅰ [9.4 % (5/53),32.8 % (42/128)] and grade Ⅲ [50.9 % (27/53),22.7 % (29/128)](P 〈 0.05).In the group of TNBC the rate of invasive lobular carcinoma [5.7 % (3/53)] and medullary carcinoma [15.1% (8/53)] were obviously different from the group of NTNBC [19.5 % (25/128),3.1% (4/128)](P 〈 0.05).The positive rates of EGFR,p53 and Ki-67 were 62.3 % (33/53),25.0 % (32/128),71.7 %(38/53) and 47.7 % (61/128),84.9 % (45/53),70.3 % (90/128) in the TNBC and NTNBC respectively,and significant differences were found between two groups (P 〈 0.05).Conclusion The higher expression of EGFR,p53,Ki-67 in TNBC is associated with the high grade with a poor prognosis,therefore,EGFR,p53,Ki-67 could be molecular markers and targets valuable for human breast cancer specially human TNBC.
出处 《肿瘤研究与临床》 CAS 2013年第10期669-671,共3页 Cancer Research and Clinic
关键词 乳腺肿瘤 三阴性乳腺癌 表皮生长因子受体 P53 KI-67 免疫组织化学 Breast carcinoma Triple negative breast carcinoma Endothelial growth factor receptor p53 Ki-67 Immunohistochemistry
  • 相关文献

参考文献7

二级参考文献118

  • 1唐波,彭志红,姜军.肼苯哒嗪与三苯氧胺协同抗雌激素受体α阴性乳腺癌的研究[J].中华实验外科杂志,2005,22(5):538-540. 被引量:9
  • 2唐波,姜军,彭志红.5氮2脱氧胞苷与三苯氧胺协同抗雌激素受体Α阴性乳腺癌的体外实验研究[J].中华外科杂志,2005,43(23):1545-1549. 被引量:5
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:165
  • 4Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
  • 5Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
  • 6Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
  • 7Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
  • 8Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
  • 9Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.
  • 10Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146.

共引文献234

同被引文献125

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部